| scholarly article | Q13442814 |
| P50 | author | John Ioannidis | Q6251482 |
| Caroline Gordon | Q58049734 | ||
| Angela Tincani | Q73304219 | ||
| Jean-Charles Piette | Q73305204 | ||
| Munther A. Khamashta | Q73418907 | ||
| Josep Font | Q73474655 | ||
| Stefano Bombardieri | Q73477457 | ||
| Cees G M Kallenberg | Q87375577 | ||
| David A. Isenberg | Q42326409 | ||
| Ronald van Vollenhoven | Q47265013 | ||
| Ricard Cervera i Segura | Q53547424 | ||
| P2093 | author name string | M Schneider | |
| J Smolen | |||
| G Sturfelt | |||
| D T Boumpas | |||
| J Boletis | |||
| F Houssiau | |||
| G Bertsias | |||
| T Huizinga | |||
| C Dostal | |||
| I M Gilboe | |||
| Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 195-205 | |
| P577 | publication date | 2007-05-15 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics | |
| P478 | volume | 67 |
| Q41926759 | A cross‐sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus |
| Q42511206 | A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full? |
| Q49359821 | A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea |
| Q41173342 | A randomized double-blind placebo-controlled study adding high dose vitamin D to analgesic regimens in patients with musculoskeletal pain |
| Q37876387 | A structured literature review of the direct costs of adult systemic lupus erythematosus in the US |
| Q35234558 | A systematic review of prevalence, disease characteristics and management of systemic lupus erythematosus in Australia: identifying areas of unmet need |
| Q43866756 | ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status? |
| Q38734009 | Abatacept for the treatment of systemic lupus erythematosus. |
| Q38006176 | Abatacept therapy and safety management |
| Q84914758 | Acute systemic lupus erythematosus on the acute medical take: are we missing anything? |
| Q53744989 | Aerobic and resistance exercise in systemic sclerosis: State of the art. |
| Q39178961 | An update on diet and nutritional factors in systemic lupus erythematosus management. |
| Q43976668 | Annual direct medical cost of active systemic lupus erythematosus in five European countries |
| Q49383501 | Antimalarial-induced cardiomyopathy: a systematic review of the literature |
| Q41916380 | Antimalarials as a risk factor for elevated muscle enzymes in systemic lupus erythematosus |
| Q41919852 | Antimalarials in the treatment of systemic lupus erythematosus: a registry-based cohort study in Denmark. |
| Q64046338 | Antiphospholipid syndrome |
| Q58602902 | Antiphospholipid syndrome: state of the art on clinical practice guidelines |
| Q34938841 | Aortic Atherosclerosis in Systemic Lupus Erythematosus |
| Q48770082 | Application of SLICC classification criteria in undifferentiated connective tissue disease and evolution in systemic lupus erythematosus: analysis of a large monocentric cohort with a long-term follow-up |
| Q57526162 | Association between vitamin D receptor (VDR) gene polymorphisms and systemic lupus erythematosus in Portuguese patients |
| Q62273234 | Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge |
| Q47220547 | Attenuation of nephritis in lupus-prone mice by thalidomide. |
| Q58766114 | Audiovestibular Symptoms in Systemic Autoimmune Diseases |
| Q50972538 | Auto-antibodies to double-stranded DNA as biomarker in systemic lupus erythematosus: comparison of different assays during quiescent and active disease |
| Q38817091 | Autoimmunity in visual loss. |
| Q26796484 | B-cell survival factors in autoimmune rheumatic disorders |
| Q37960525 | Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus |
| Q90460781 | Baricitinib for systemic lupus erythematosus |
| Q30645037 | Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials |
| Q46364779 | Belimumab for systemic lupus erythematosus: a practice-based view |
| Q26778277 | Belimumab in systemic lupus erythematosus |
| Q38810737 | Belimumab in the management of systemic lupus erythematosus - an update |
| Q36094045 | Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response |
| Q49355618 | Belimumab: A Review in Systemic Lupus Erythematosus |
| Q84583299 | Biological therapy for lupus nephritis-tribulations and trials |
| Q38799791 | Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser |
| Q58570637 | Bulgarian rheumatology: science and practice in a cost-constrained environment |
| Q44615394 | Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel |
| Q88956497 | Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature |
| Q26858863 | Cardiac tamponade as the first manifestation of systemic lupus erythematosus in children: Table 1 |
| Q90415557 | Cerebrovascular Events in Systemic Lupus Erythematosus: Diagnosis and Management |
| Q44862702 | Changes in Farr radioimmunoassay and EliA fluorescence immunoassay anti-dsDNA in relation to exacerbation of SLE. |
| Q35992235 | Characteristics of azathioprine use and cessation in a longitudinal lupus cohort. |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q41913974 | Chloroquine-induced subacute paranoid-like disorder as a complication of dermatological treatment |
| Q36766114 | Classification criteria for neuropsychiatric systemic lupus erythematosus: do they need a discussion? |
| Q34478853 | Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials |
| Q47133837 | Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey. |
| Q53431647 | Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases |
| Q89701941 | Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice |
| Q52916537 | Comparative Efficacies of Long-Term Serial Transplantation of Syngeneic, Allogeneic, Xenogeneic, or CTLA4Ig-Overproducing Xenogeneic Adipose Tissue-Derived Mesenchymal Stem Cells on Murine Systemic Lupus Erythematosus. |
| Q36152835 | Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences |
| Q37487299 | Conflicts of interest in biomedical publications: considerations for authors, peer reviewers, and editors. |
| Q84403993 | Connective tissue diseases: Lupus nephritis-winning a few battles but not the war |
| Q41299263 | Connective tissue diseases: The burden of serious infections in SLE. |
| Q41540102 | Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis |
| Q36443689 | Contemporary treatment of systemic lupus erythematosus: an update for clinicians. |
| Q37456307 | Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials |
| Q37954539 | Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report |
| Q38262100 | Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus |
| Q38380629 | Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines |
| Q41930958 | Differences between rheumatologists and other internists regarding diagnosis and treatment of systemic lupus erythematosus |
| Q51572777 | Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus |
| Q52805150 | Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity |
| Q47143263 | Drug utilization and therapy provision patterns by prescriber types among patients with systemic lupus erythematosus in Korea |
| Q40047389 | Drugs used in incident systemic lupus erythematosus - results from the Finnish nationwide register 2000-2007. |
| Q37763266 | EFNS guidelines on diagnosis and management of neuromyelitis optica |
| Q87984753 | Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies |
| Q47856207 | Effects of a one-year physical activity programme for women with systemic lupus erythematosus - a randomized controlled study |
| Q46083219 | Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-week Randomized, Placebo-Controlled, Phase IIb Study |
| Q28304807 | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial |
| Q57469182 | Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study |
| Q35568194 | Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis |
| Q36672666 | Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab |
| Q40799533 | Epidemiology and risk factors for chronic kidney disease in Chinese patients with biopsy-proven lupus nephritis |
| Q44480906 | Established medications : new areas of application |
| Q46496211 | Ethnicity in systemic lupus erythematosus (SLE): its influence on susceptibility and outcomes |
| Q34187282 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies |
| Q37391863 | European consensus statement on the terminology used in the management of lupus glomerulonephritis |
| Q39053375 | Evaluation of quality indicators and disease damage in childhood-onset systemic lupus erythematosus patients |
| Q33602398 | Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus |
| Q41187106 | Fever of unknown origin in a male patient with systemic lupus erythematosus |
| Q64924819 | First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatolog |
| Q30490276 | First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study. |
| Q47557472 | Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort |
| Q34918643 | Guidelines on the use of extracorporeal photopheresis |
| Q34114253 | Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus |
| Q55507790 | Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. |
| Q58608203 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care |
| Q64244455 | Immune Profiling and Precision Medicine in Systemic Lupus Erythematosus |
| Q35891974 | Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune disease: a Phase III, open-label, single-arm, multicenter study |
| Q30832692 | Improving care delivery and outcomes in pediatric rheumatic diseases |
| Q42162220 | Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy |
| Q51152425 | Inflammation-related cardiovascular morbidity : Pathophysiology and therapy |
| Q38071798 | Innate immune processes in lupus erythematosus |
| Q90139245 | Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme |
| Q38086806 | International Consensus for Provisions of Quality‐Driven Care in Childhood‐Onset Systemic Lupus Erythematosus |
| Q38852129 | Is there still a place for erythrocyte sedimentation rate and C-reactive protein in systemic lupus erythematosus? |
| Q36302245 | Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis |
| Q38854545 | Juvenile systemic lupus erythematosus: onset patterns and short-term outcome in Egyptian children, a single-center experience |
| Q46260498 | Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response |
| Q36165790 | Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-up |
| Q40725518 | Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study |
| Q37969656 | Lupus arthritis--do we have a clinically useful classification? |
| Q38643755 | Lupus nephritis and B-cell targeting therapy. |
| Q34299943 | Lupus nephritis: A critical review |
| Q34638296 | Lupus: an overview of the disease and management options |
| Q64060940 | MMP-9/Gelatinase B Degrades Immune Complexes in Systemic Lupus Erythematosus |
| Q26774815 | Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives |
| Q44393048 | Managing comorbidities of inflammatory rheumatic diseases |
| Q37129534 | Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis |
| Q47841813 | Measuring educational needs among patients with systemic lupus erythematosus (SLE) using the Dutch version of the Educational Needs Assessment Tool (D-ENAT). |
| Q37914899 | Measuring outcomes in systemic lupus erythematosus clinical trials |
| Q90257324 | Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review |
| Q35156885 | Memantine in Systemic Lupus Erythematosus: A Randomized, Double-Blind Placebo-Controlled Trial |
| Q35091202 | Methods of formal consensus in classification/diagnostic criteria and guideline development |
| Q46901557 | Modern therapy for systemic lupus erythematosus |
| Q35907818 | Mutations in genes encoding complement inhibitors CD46 and CFH affect the age at nephritis onset in patients with systemic lupus erythematosus |
| Q44606491 | Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study |
| Q54975027 | NUDT15 R139C Variants Increase the Risk of Azathioprine-Induced Leukopenia in Chinese Autoimmune Patients. |
| Q37995457 | Neuropsychological assessment in mixed connective tissue disease: comparison with systemic lupus erythematosus |
| Q90412368 | New therapeutic strategies in systemic lupus erythematosus management |
| Q35752030 | New treatment options for lupus - a focus on belimumab. |
| Q92625516 | Novel paradigms in systemic lupus erythematosus |
| Q37704576 | Obesity and cytokines in childhood-onset systemic lupus erythematosus |
| Q38225438 | Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role |
| Q33574487 | Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations |
| Q33552640 | Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community |
| Q47960665 | Patient-reported fatigue and its impact on patients with systemic lupus erythematosus |
| Q35502338 | Periodontal findings in systemic lupus erythematosus patients and healthy controls |
| Q39680831 | Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging stu |
| Q37510905 | Pharmacotherapy of systemic lupus erythematosus. |
| Q48434991 | Physical activity in patients with systemic lupus erythematosus and matched controls |
| Q91868543 | Pneumococcal Polysaccharide Vaccine Ameliorates Murine Lupus |
| Q38672493 | Post-marketing surveillance study of the long-term use of mizoribine for the treatment of lupus nephritis: 2-Year results |
| Q58051940 | Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans? |
| Q38156069 | Pragmatic approaches to therapy for systemic lupus erythematosus |
| Q42634173 | Predictive biological markers of systemic lupus erythematosus flares: a systematic literature review. |
| Q38241501 | Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis |
| Q92485957 | Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus |
| Q35407695 | Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. |
| Q36570988 | Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies |
| Q37640274 | Presentation of SLE in UK primary care using the Clinical Practice Research Datalink |
| Q38851096 | Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care |
| Q84227534 | Primary prevention in antiphospholipid antibody carriers |
| Q36766244 | Progressive Multifocal Leukoencephalopathy and Systemic Lupus Erythematosus: Focus on Etiology |
| Q33945242 | Quality of care for incident lupus nephritis among Medicaid beneficiaries in the United States |
| Q93008976 | Quality of care predicts outcome in systemic lupus erythematosus: a cross-sectional analysis of a German long-term study (LuLa cohort) |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q47124937 | Rare complicated parapneumonic effusion, Mycoplasma pneumoniae with new-onset lupus flare: Case report and literature review |
| Q34707551 | Recurrent lower motor neuron type facial palsy: an unusual manifestation of SLE |
| Q35631844 | Relationship between hypoalbuminemia, hyperlipidemia and renal severity in patients with lupus nephritis: a prospective study |
| Q49480873 | Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study |
| Q50882478 | Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. |
| Q57464055 | Reversible Cognitive Dysfunction in Elderly-onset Systemic Lupus Erythematosus, Successfully Treated with Aggressive Immunosuppressive Therapy |
| Q33692770 | Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety |
| Q37678723 | Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. |
| Q37556428 | Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus |
| Q37541561 | Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases |
| Q37737138 | Rituximab therapy in lupus nephritis: current clinical evidence |
| Q52836583 | S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). |
| Q37077223 | Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus |
| Q43775404 | Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus |
| Q52861033 | Shared decision making even for complex systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE)? |
| Q88477714 | Sharp decline in hydroxychloroquine dosing-analysis of 17,797 initiators from 2007 to 2016 |
| Q36844513 | Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study |
| Q33599297 | Simultaneous assessment of rotavirus-specific memory B cells and serological memory after B cell depletion therapy with rituximab |
| Q43663302 | Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares |
| Q58204824 | Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus |
| Q45090317 | Soluble Receptor for Advanced Glycation End Products Alleviates Nephritis in (NZB/NZW)F1 Mice |
| Q44108515 | Statement on the use of mycophenolate mofetil for systemic lupus erythematosus |
| Q38844621 | Stroke in systemic lupus erythematosus and antiphospholipid syndrome: risk factors, clinical manifestations, neuroimaging, and treatment |
| Q38605480 | Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration |
| Q59789656 | Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction |
| Q43600133 | Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study |
| Q22299249 | Survival in systemic lupus erythematosus, 1995-2010. A prospective study in a Danish community |
| Q37782039 | Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators |
| Q55282858 | Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. |
| Q38080362 | Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options |
| Q44213235 | Systemic lupus erythematosus |
| Q37900778 | Systemic lupus erythematosus – an update |
| Q50848358 | Systemic lupus erythematosus. |
| Q52913359 | Systemic lupus erythematosus. Target criteria for treatment |
| Q60050042 | Systemic lupus erythematosus: state of the art on clinical practice guidelines |
| Q26741149 | Systemic lupus erythematosus: strategies to improve pregnancy outcomes |
| Q35692998 | The Diagnosis and Treatment of Systemic Lupus Erythematosus |
| Q91790202 | The Enlargement of Abdominal Lymph Nodes Is a Characteristic of Autoimmune Liver Disease |
| Q92816495 | The Impact of Cytokines on the Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus |
| Q58102052 | The association of CD40 polymorphism (rs1883832C/T) and soluble CD40 with the risk of systemic lupus erythematosus among Egyptian patients |
| Q28072610 | The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus |
| Q42228462 | The effect of comorbidity on hospital mortality in patients with SLE from an Asian tertiary hospital |
| Q88801489 | The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease |
| Q37715138 | The outcome of patients with lupus nephritis and the impact of cardiovascular risk factors |
| Q34318285 | The treatment strategies of autoimmune disease may need a different approach from conventional protocol: A review |
| Q37627356 | The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness |
| Q34597321 | The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects |
| Q51300605 | Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study |
| Q37642828 | Thrombosis in systemic lupus erythematosus: risk and protection |
| Q38752229 | Toward electronic health recording: evaluation of electronic patient reported outcome measures (e-PROMs) system for remote monitoring of early systemic lupus patients. |
| Q92208812 | Transcriptomics analysis of sirolimus treatment in lupus nephritis |
| Q41207949 | Treatment Algorithms in Systemic Lupus Erythematosus |
| Q47102324 | Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure |
| Q33907242 | Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view |
| Q34512800 | Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial |
| Q56907356 | Trial of SLE therapies in real-world settings |
| Q38864797 | Update on Biologic Therapies for Systemic Lupus Erythematosus |
| Q37255744 | Update on the management of lupus nephritis: let the treatment fit the patient |
| Q40700770 | Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years |
| Q40181738 | Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study |
| Q37854968 | Vitamin D Endocrine System and the Immune Response in Rheumatic Diseases |
| Q56959883 | [Biologics therapy for systemic lupus erythematosus. Current situation] |
| Q84815168 | [Changes in mortality and morbidity in systemic lupus erythematosus] |
| Q81939493 | [Lupus erythematodes--evidence-based recommendations for monitoring and therapy] |
| Q90173325 | [Oral glucocorticoids : Therapeutic use and treatment monitoring in inflammatory rheumatic diseases] |
| Q85927205 | [Overcoming disease in systemic lupus erythematosus] |
| Q84593027 | [Pregnancy and inflammatory rheumatic diseases] |
| Q84566584 | [Systemic lupus erythematosus. A problem based approach] |
| Q89894663 | [Tapering and termination of immunosuppressive therapy : Systemic lupus erythematosus] |
| Q84274457 | [The process of generating EULAR recommendations] |
| Q87078574 | [Therapeutic strategies for systemic lupus erythematosus] |
Search more.